Predictors of Recurrent Severe Hypoglycemia in Adults With Type 1 Diabetes and Impaired Awareness of Hypoglycemia During the HypoCOMPaSS Study.


Journal

Diabetes care
ISSN: 1935-5548
Titre abrégé: Diabetes Care
Pays: United States
ID NLM: 7805975

Informations de publication

Date de publication:
01 2020
Historique:
received: 28 03 2019
accepted: 06 08 2019
pubmed: 6 9 2019
medline: 3 10 2020
entrez: 6 9 2019
Statut: ppublish

Résumé

The HypoCOMPaSS study was designed to test the hypothesis that successful avoidance of biochemical hypoglycemia without compromising overall glycemic control would restore sufficient hypoglycemia awareness to prevent recurrent severe hypoglycemia in the majority of participants with established type 1 diabetes. Before starting the study, we planned to investigate associations between baseline characteristics and recurrent severe hypoglycemia over 2 years' follow-up. A total of 96 adults with type 1 diabetes and impaired awareness of hypoglycemia participated in a 24-week 2 × 2 factorial randomized controlled trial comparing insulin delivery and glucose monitoring modalities, with the goal of rigorous biochemical hypoglycemia avoidance. The analysis included 71 participants who had experienced severe hypoglycemia in the 12-month prestudy with confirmed absence (complete responder) or presence (incomplete responder) of severe hypoglycemia over 24 months' follow-up. There were 43 (61%) complete responders and 28 (39%) incomplete responders experiencing mean ± SD 1.5 ± 1.0 severe hypoglycemia events/person-year. At 24 months, incomplete responders spent no more time with glucose ≤3 mmol/L (1.4 ± 2.1% vs. 3.0 ± 4.8% for complete responders; Recurrent severe hypoglycemia was associated with higher preintervention severe hypoglycemia rate, fear of hypoglycemia, and concomitant neuropathy.

Identifiants

pubmed: 31484666
pii: dc19-0630
doi: 10.2337/dc19-0630
doi:

Substances chimiques

Blood Glucose 0
Insulin 0

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

44-52

Informations de copyright

© 2019 by the American Diabetes Association.

Auteurs

Anneliese J S Flatt (AJS)

Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, U.K.
Newcastle Diabetes Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, U.K.

Stuart A Little (SA)

Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, U.K.
Newcastle Diabetes Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, U.K.

Jane Speight (J)

School of Psychology, Deakin University, Geelong, Victoria, Australia.
The Australian Centre for Behavioural Research in Diabetes, Diabetes Victoria, Melbourne, Victoria, Australia.
AHP Research, Hornchurch, U.K.

Lalantha Leelarathna (L)

Wellcome Trust-MRC Institute of Metabolic Science Metabolic Research Laboratories, University of Cambridge, Cambridge, U.K.

Emma Walkinshaw (E)

School of Medicine and Biomedical Sciences, The University of Sheffield, Sheffield, U.K.

Horng Kai Tan (HK)

Peninsula College of Medicine and Dentistry, Plymouth, U.K.

Anita Bowes (A)

Bournemouth Diabetes and Endocrine Centre, Royal Bournemouth Hospital, Bournemouth, U.K.

Alexandra Lubina-Solomon (A)

School of Medicine and Biomedical Sciences, The University of Sheffield, Sheffield, U.K.

Elizabeth Holmes-Truscott (E)

Newcastle Diabetes Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, U.K.
School of Psychology, Deakin University, Geelong, Victoria, Australia.

Thomas J Chadwick (TJ)

Institute of Health & Society, Newcastle University, Newcastle upon Tyne, U.K.

Ruth Wood (R)

Newcastle Clinical Trials Unit, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, U.K.

Timothy J McDonald (TJ)

Institute of Biomedical and Clinical Science, College of Medicine and Health, University of Exeter, Exeter, U.K.

David Kerr (D)

Bournemouth Diabetes and Endocrine Centre, Royal Bournemouth Hospital, Bournemouth, U.K.
Sansum Diabetes Research Institute, Santa Barbara, CA.

Daniel Flanagan (D)

Peninsula College of Medicine and Dentistry, Plymouth, U.K.

Augustin Brooks (A)

Bournemouth Diabetes and Endocrine Centre, Royal Bournemouth Hospital, Bournemouth, U.K.

Simon R Heller (SR)

School of Medicine and Biomedical Sciences, The University of Sheffield, Sheffield, U.K.

Mark L Evans (ML)

Wellcome Trust-MRC Institute of Metabolic Science Metabolic Research Laboratories, University of Cambridge, Cambridge, U.K.

James A M Shaw (JAM)

Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, U.K. jim.shaw@ncl.ac.uk.
Newcastle Diabetes Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, U.K.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH